(19)
(11) EP 1 504 035 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.02.2018 Bulletin 2018/09

(45) Date of publication and mention of the limitation decision:
B3-1 20.12.2017 Bulletin 2017/51

(45) Mention of the grant of the patent:
31.03.2010 Bulletin 2010/13

(21) Application number: 03718974.3

(22) Date of filing: 02.05.2003
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
C12N 15/85(2006.01)
A61K 39/395(2006.01)
A61P 35/00(2006.01)
 C12N 15/13(2006.01)
C12N 5/10(2006.01)
A61K 31/7088(2006.01)
(86) International application number:
PCT/GB2003/001934
(87) International publication number:
WO 2003/093320 (13.11.2003 Gazette 2003/46)

(54)

ANTIBODIES SPECIFIC FOR HUMAN CD22 AND THEIR THERAPEUTIC AND DIAGNOSTIC USES

ANTIKÖRPER GEGEN HUMANES CD22 UND DEREN THERAPEUTISCHE UND DIAGNOSTISCHE VERWENDUNGEN

ANTICORPS SPECIFIQUES A L' HUMAIN CD22 ET LEURS UTILISATION THERAPEUTIQUES ET DIAGNOSTIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 02.05.2002 GB 0210121

(43) Date of publication of application:
09.02.2005 Bulletin 2005/06

(73) Proprietor: UCB Pharma, S.A.
1070 Brussels (BE)

(72) Inventors:
  • POPPLEWELL, Andrew George
    Slough, Berkshire SL1 3WE (GB)
  • TICKLE, Simon Peter
    Slough, Berkshire SL1 3WE (GB)
  • LADYMAN, Heather Margaret
    Slough, Berkshire SL1 3WE (GB)

(74) Representative: Mercer, Christopher Paul et al
Carpmaels & Ransford LLP One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A-00/31141
WO-A-01/94585
WO-A-92/15683
WO-A-96/04925
US-A- 5 714 350
 WO-A-00/74718
WO-A-91/09967
WO-A-94/29451
WO-A-98/19704
   
  • S. LEUNG ET AL.: "Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2." MOLECULAR IMMUNOLOGY, vol. 32, no. 17/18, December 1995 (1995-12), pages 1413-1427, XP000942678 Oxford, GB
  • S. LEUNG ET AL.: "Effect of Vk framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site." INTERNATIONAL JOURNAL OF CANCER, vol. 60, 1995, pages 534-538, XP002066554 New York, NY, USA
  • I. BENHAR ET AL.: "Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization." BIOCONJUGATE CHEMISTRY, vol. 5, July 1994 (1994-07), pages 321-326, XP000564453 Washington, DC, USA
  • T. VAUGHAN ET AL.: "Human antibodies by design." NATURE BIOTECHNOLOGY, vol. 16, June 1998 (1998-06), pages 535-539, XP000941675 New York, NY, USA cited in the application
  • J. CARNAHAN ET AL.: "Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties." CLINICAL CANCER RESEARCH, vol. 9, no. suppl., 1 September 2003 (2003-09-01), pages 3982S-3990S,
  • J. DIJOSEPH ET AL.: "Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22." CANCER IMMUNOLOGY & IMMUNOTHERAPY, vol. 54, 2005, pages 11-24,
  • J. DIJOSEPH ET AL.: "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies." BLOOD, vol. 103, no. 5, 1 March 2004 (2004-03-01), pages 1807-1814,
  • S. VAN ROSSENBERG ET AL.: "A structure-function study of ligand recognition by CD22beta." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 16, 20 April 2001 (2001-04-20), pages 12967-12973, U.S.A.
  • J. BROWNING: "B cells move to centre stage: Novel opportunities for autoimmune disease treatment." NATURE REVIEWS DRUG DISCOVERY, vol. 5, no. 7, July 2006 (2006-07), pages 564-576,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).